Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.6B
150M shares
52-week range
$18.01 – $36.80
29% from low
Sector
SERVICES-HOME HEALTH CARE SERVICES
Exchange
NASDAQ
CS
P/S (TTM)
0.6
EV / FCF (TTM)
13.7
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
www.optioncarehealth.comNo one on the platform currently holds OPCH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 558,926 | $15.0M |
| Bridgewater Associatesas of 2025-09-30 | 7,404 | $205.5K |
| Execution date | Ratio |
|---|---|
| 2020-02-03 | 1-for-4reverse |
No one on the platform has traded OPCH yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.5% | 10.0% | — | — | — | |
| Rev. Growth % | 13.0% | 13.3% | ||||
| Profit Margin % | 3.7% | 4.4% | 0.6% | |||
| Free Cash Flow Margin % | 3.8% | 5.7% | 2.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +3.1% on the P/E track.
At today's price, your expected annual return is +8.3% on the P/E track.
At today's price, your expected annual return is +12.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.8B | +1.9% | $1.88 | $1.85–$1.93 | 12.5× | 8 |
| 2027 | $6.1B | +6.6% | $2.08 | $2.00–$2.13 | 11.3× | 8 |
| 2028 | $6.6B | +8.2% | $2.32 | $2.16–$2.43 | 10.1× | 5 |
| 2029 | $7.2B | +8.8% | $2.55 | $2.52–$2.59 | 9.2× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.43 | $0.45 | +5.6% |
| 2026-04-30 | $0.37 | $0.40 | +8.1% |
| 2026-02-24 | $0.46 | $0.46 | +0.0% |
| 2025-10-30 | $0.43 | $0.45 | +4.7% |
| 2025-07-30 | $0.40 | $0.41 | +2.5% |
| 2025-04-29 | $0.36 | $0.40 | +11.1% |
| 2025-02-26 | $0.33 | $0.35 | +6.1% |
| 2024-10-30 | $0.31 |
| $0.31 |
| +0.0% |
| $7.3B |
| — |
| IMVTImmunovant, Inc. | $37.66 | +0.80% | $7.8B | — |
| INDVIndivior Pharmaceuticals Inc | $34.47 | -0.06% | $4.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
$OPCH My Quant does all the work for me. All I do is press a couple buttons. 😊
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-7-29-option-care-health-inc-stock/ $OPCH Option Care Health Earnings Transcript
View on StockTwits ↗
$OPCH Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.35 up 12.90% YoY • Reported revenue of $1.44B up 1.86% YoY • For full year 2026, Option Care Health expects net revenue of $5.675 billion to $5.775 billion, Adjusted EBITDA of $480 million to $495 million, and Adjusted diluted EPS of $1.85 to $1.92.
View on StockTwits ↗
$OPCH starting to look undervalued even with biosim and sub q headwinds. They are able to buy better and reduce total non clinical costs per case than any player in the space. They are the only ones able to perform in acute space as well.
View on StockTwits ↗
$OPCH Share Price: $22.27 Contract Selected: Jan 15, 2027 $20 Calls Buy Zone: $3.40 – $4.20 Target Zone: $6.39 – $7.81 Potential Upside: 77% ROI Time to Expiration: 210 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$OPCH Brilliant piece that captures OPCH's situation perfectly. So if you want to update your understanding of OPCH or get to know OPCH better, this is essential reading. https://everyticker.com/quote/OPCH/analysis/option-care-health-turning-a-therapeutic-reset-into-a-structural-advantage-nasdaq-opch
View on StockTwits ↗
$OPCH CEO purchased 12,500 shares at $21.18 for a total of $264,706. RADEMACHER JOHN CHARLES now owns 695,152 shares. https://ceo-buys.com
View on StockTwits ↗
$OPCH CEO and CFO purchased additional shares: https://www.sec.gov/Archives/edgar/data/1014739/000143774926014692/xslF345X06/rdgdoc.xml https://www.sec.gov/Archives/edgar/data/1014739/000143774926014693/xslF345X06/rdgdoc.xml
View on StockTwits ↗
$OPCH we nailed the bottom on our discord other day, join for more picks like this https://whop.com/joined/catalyst-research-by-marketsiren/
View on StockTwits ↗
$OPCH Classic stop loss raid then a lockout rally what's new?
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.